首页> 外国专利> HUMAN BRAIN ENDOTHELIAL CELLS AND GROWTH MEDIUM AND METHOD FOR EXPANSION OF PRIMITIVE CD34+CD38 - BONE MARROW STEM CELLS

HUMAN BRAIN ENDOTHELIAL CELLS AND GROWTH MEDIUM AND METHOD FOR EXPANSION OF PRIMITIVE CD34+CD38 - BONE MARROW STEM CELLS

机译:人脑内皮细胞和生长培养基及原代CD34 + CD38-骨髓基质干细胞的扩增方法

摘要

A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34+CD38- cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34+ cells on HUBEC monolayers supplemented with GM-CSF+IL-3+IL-6+SCF+flt-3 ligand caused a 14.5-fold increase in total cells, an 6.6-fold increase in CD34+ cells, and, most remarkably, a 440-fold increase in CD34+CD38- cells after 7 days. Further, CFU-GM production increased 15.1-fold, BFU-E increased 8-fold and CFU-Mix increased 5.2-fold. Optimal generation was dependent upon the continued presence of exogenous supplied cytokines. In comparison, identically treated stroma-free suspension cultures supported a 10.2-fold expansion of total cells, a 3-fold increase in CD34+ cells and maintained the CD34+CD38- cell pool after 7 days of culture. Moreover, we found that non-brain human endothelial cells isolated from the same donors supported neither the expansion nor the maintenance of human CD34+CD38- cells. Although few steady state CD34+CD38- cells give rise to visible colony-forming cells in methylcellulose cultures, our FACS based cell cycle and sorting experiments demonstrated the activation of a highly clonogenic CD34+CD38- population (24 % cloning efficiency) during ex-vivo culture on cytokine treated HUBEC. These results suggest that bone marrow CD34+CD38- cells require a stromal cell microenvironment for optimal expansion and that ex-vivo expanded CD34+CD38- cells generated in the HUBEC culture system appear to retain some degree of primitive 'stemness'.
机译:公开了一种新颖的使用人脑内皮细胞(HUBEC)的共培养系统,该系统促进了与PMVEC系统一致的人CD34 + CD38-细胞的扩增。从尸体供体中分离出HUBEC,在原代培养中进行传代,克隆后发现其为Von Willebrand因子阳性。在补充了GM-CSF + IL-3 + IL-6 + SCF + flt-3配体的HUBEC单层上纯化骨髓CD34 +细胞的培养导致总细胞增加14.5倍,CD34 +细胞增加6.6倍,最显着的是,7天后CD34 + CD38-细胞增加了440倍。此外,CFU-GM产量增加了15.1倍,BFU-E增加了8倍,CFU-Mix增加了5.2倍。最佳产生取决于外源提供的细胞因子的持续存在。相比之下,经过相同处理的无基质悬浮培养物支持培养7天后,总细胞扩展了10.2倍,CD34 +细胞增加了3倍,并保持了CD34 + CD38-细胞池。此外,我们发现从相同供体分离的非脑人内皮细胞不支持人CD34 + CD38-细胞的扩增或维持。尽管很少有稳态CD34 + CD38-细胞在甲基纤维素培养物中产生可见的集落形成细胞,但我们基于FACS的细胞周期和分选实验表明,在分离前的过程中,高克隆性CD34 + CD38-群体的激活(克隆效率为24%)。在细胞因子处理的HUBEC上进行体内培养。这些结果表明,骨髓CD34 + CD38-细胞需要基质细胞微环境以实现最佳扩增,并且HUBEC培养系统中产生的离体扩增CD34 + CD38-细胞似乎保留了一定程度的原始“干性”。

著录项

  • 公开/公告号IL143085B

    专利类型

  • 公开/公告日2006-08-20

    原文格式PDF

  • 申请/专利权人 NAVAL MEDICAL RESEARCH CENTER;

    申请/专利号IL143085

  • 发明设计人

    申请日2001-05-10

  • 分类号A61K35/12;A61K35/28;A61P7/00;A61P43/00;C12N5/0789;C12R1/91;

  • 国家 IL

  • 入库时间 2022-08-21 21:39:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号